article thumbnail

WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats

Fierce Pharma

New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. | federal funding has sent shares tumbling in recent days.

Biopharma 307
article thumbnail

Biopharma staffers exhausted and susceptible to burnout, report says

Fierce Pharma

Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52

Biopharma 304
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Capturing COVID: Biopharma through the lens during the pandemic

Fierce Pharma

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. After wreaking havoc on a pandemic level for more than three years, COVID-19 has entered its first endemic season. | Now, we’re showcasing those precious memories here.

Biopharma 178
article thumbnail

In biopharma, employees at Novartis, GSK, AZ and Genentech are most satisfied with their compensation: analysis

Fierce Pharma

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma 227
article thumbnail

Embracing Personalization in Biopharma Patient Support Programs

Fierce Pharma

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246
article thumbnail

With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of Seagen

Fierce Pharma

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 281
article thumbnail

FTC, amid biopharma M&A drive, says it will take action against 'sham' patents

Fierce Pharma

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 222